BTX doses 1st patient | LCTX Message Board Posts

Lineage Cell Therapeutics

  LCTX website

LCTX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  204 of 207  at  7/12/2019 10:11:35 AM  by

Sixty2nds


BTX doses 1st patient

https://seekingalpha.com/news/3477174-biotime-doses-first-patient-new-formulation-opregen

BioTime doses first patient with new formulation of OpRegen

Jul. 11, 2019 11:23 AM ET|About: BioTime, Inc. (BTX)|By: Douglas W. House, SA News Editor
The first patient has been dosed with BioTime's (BTX) new off-the-shelf Thaw-and-Inject formulation of OpRegen using the Orbit Subretinal Delivery System (Orbit SDS) in a Phase 1/2a clinical trial in patients with dry age-related macular degeneration.

The company says Orbit SDS enables the precise administration of OpRegen cells to the back of the eye, leading to improved dose control and greater safety.

OpRegen is a retinal pigment epithelium (RPE) transplant therapy consisting of RPE cells delivered under the retina via intraocular injection.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 91
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...